Money Matters - Simplified

Abbott Laboratories' device 'MitraClip' safer than open heart surgery

The researchers are of the view that MitraClips would be of immense help to the elderly who are reluctant or unable to undergo open heart surgery.

A new study has claimed that MitraClips are safer and more efficient than open heart surgeries for heart-valve repairs.

The device is helpful for the treatment of mitral regurgitation, and is administered to the patient through a blood vessel in the leg,

The researchers are of the view that it would be of immense help to the elderly who are reluctant or unable to undergo open heart surgery.

"This is a stunning difference in safety for an acceptable trade-off in efficacy for many patients," said Dr.Ted Feldman, director of the cardiac catheterization laboratory at NorthShore University HealthSystem in suburban Chicago.

Details of the study
The study looked at heart patients who were given the clip treatment for 30 days.

The researchers compared 12 adverse events like a major stroke, death, bleeding and heart attacks in patients with clip treatment and those undergoing surgeries.

Results of the study
The study found that out of the patients who were administered the device, 9.6 percent suffered major problems as compared to the 57 percent of the open surgery group who faced adverse problems.

MitraClip works on mitral regurgitation (MR), a fault in the valves that causes blood to flow backward in the heart, affecting nearly 250000 people in the nation every year.

It was further revealed that of the 57 percent major sufferers, at least 42 events were that of excessive bleeding.

None of the clip patients faced death, attacks or any major stroke, and less than 10 percent patients dealt with any serious side effects after the treatment.

The researchers informed that in about a year the patients showed significant improvement in their heart functioning and could undertake normal physical activity.

The hospital stay for the clip patients was approximately one third of that of a surgery patient, making the treatment much more comfortable and easy.

MitraClip
The device works on mitral regurgitation (MR), a fault in the valves that causes blood to flow backward in the heart, affecting nearly 250000 people in the nation every year.

MitraClip functions by clipping the leaflets of the mitral valve, preventing the backward flow of blood.

Researchers believe that the success of the study would help Abbott get the approval for selling the devices in the nation.

Dr. Ted Feldman, who presented the data at the American College of Cardiology scientific meeting in Atlanta, called it one of the best safety results he had ever seen in a heart procedure.